A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants
NCT ID: NCT00479648
Last Updated: 2016-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
612 participants
INTERVENTIONAL
2007-05-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults
NCT00562484
A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine
NCT01265914
Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)
NCT00310648
Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above
NCT02126761
Phase 1b Influenza Vaccine Study in Healthy Subjects
NCT01181336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Inactivated trivalent influenza vaccine
Inactivated trivalent influenza vaccine
2
CSL412 formulation
CSL412
3
CSL412 formulation
CSL412
4
CSL412 formulation
CSL412
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CSL412
Inactivated trivalent influenza vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide pre-vaccination venous blood sample
Exclusion Criteria
* Immunomodulative therapy
* Acute infection
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seqirus
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CSL Limited
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elizabeth Hancox, Dr
Role: PRINCIPAL_INVESTIGATOR
Chiltern International
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chiltern International
Slough, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSLCT-IIV-06-27
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.